美国最高法院近日就一起备受关注的“简化标签”专利纠纷案作出裁决,支持仿制药制造商HIKMA,该案涉及阿玛琳公司的心脏药物Vascepa。这一判决为仿制药行业在特定专利规避策略的运用上提供了重要的法律支持。
美国最高法院近日就一起备受关注的“简化标签”专利纠纷案作出裁决,支持仿制药制造商HIKMA,该案涉及阿玛琳公司的心脏药物Vascepa。这一判决为仿制药行业在特定专利规避策略的运用上提供了重要的法律支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.